

NEWS RELEASE

HYDERABAD, INDIA (18 June' 2020) -- SUVEN Pharmaceuticals Limited ("SPL", "Company") today announced audited financial results for the quarter and year ended 31 Mar 2020. The audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 18 June' 2020 at Hyderabad.

CONDENSED STATEMENT OF OPERATIONS				All figures in INR Lakhs, except EPS			
	Stand Alone - 3 Months ended			FY-Stand Alone (1)		FY-Consolidated (2)	
	Q4 Mar 20	Q3 Dec 19	Q4 Mar 19	FY Mar 20	FY Mar 19	FY Mar 20	FY Mar 19
Revenue	19,010.46	18,359.37	25,133.38	85,190.70	37,843.47	85,190.70	37,843.47
Operational expenses	10,740.78	9,904.67	12,890.74	44,864.41	20,628.16	40,326.31	20,628.16
Depreciation and Amortisation	705.34	559.94	595.67	2,386.01	1,149.68	2,386.01	1,149.68
Finance cost	720.37	717.56	174.34	2,181.26	278.92	2,027.21	278.92
Total expenses	12,166.49	11,182.17	13,660.75	49,431.68	22,056.76	44,739.53	22,056.76
Tax	1,519.90	1,977.35	3,990.33	8,751.00	4,859.28	8,751.00	4,859.28
Profit After Tax for the period/year	5,324.07	5,199.85	7,482.30	27,008.02	10,927.43	31,700.17	10,927.43
Other comprehensive income	(13.85)	(62.45)	-	(81.80)	-	(81.80)	-
Total comprehensive income	5,310.22	5,137.40	7,482.30	26,926.22	10,927.43	31,618.37	10,927.43
Paid up equity capital	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82
Earnings per share of Rs.1 each (EPS)	4.18	4.09	5.88	21.22	8.59	24.91	8.59

(1) Post demerger, as approved by Honorable National Company Law Tribunal (NCLT) on 6 Jan 2020, your Company has become Resultant entity with the appointed date effective 1 Oct 2018 and hence the annual figures of previous year are not comparable

(2) On consolidation of the accounts of Suven Pharma, Inc., USA, wholly owned subsidiary, the PAT includes INR 4,821 lakhs of unrealised share of profit in Rising Pharma Holdings, Inc., USA, an associate company.

- The Company is focused on the business of Contract Development and Manufacturing Operations (CDMO).
- During the year, Suven Life Sciences Limited, (Group company), a 30 years old entity, demerged CRAMS business undertaking, now integrated to your Company and the Group Company retained discovery research and clinical development of new molecules focused on Central Nervous System (CNS) disorders.
- During the year your Company invested through Suven Pharma, Inc., for a minority stake in Rising Pharma Holdings, Inc., a generic formulations development and distribution entity, operating out of New Jersey, USA.
- There was a fire accident on 26 April 2020 at one of the Company's buildings having research facilities in Jeedimetla, Hyderabad and the insurance claim under process.
- On 30 Jan 2020, the World Health Organization (WHO) declared the coronavirus (COVID-19) outbreak a "Public Health Emergency of International Concern" and on 11 Mar 2020, declared it to be pandemic. Actions taken around the world to help mitigate the spread of the coronavirus include restrictions on travel, quarantines in certain areas and forced closure for certain types of public places and businesses. The actions taken to mitigate the spread expected to continue for more time and may have adverse impact on economics in different geographies in which your Company operates. It is unknown for how long the adverse conditions associated with COVID-19 will last. To date, the Company has not experienced any major consequences or loss of business which will materially impact the financial conditions of the Company.

Risk Statement:

Except for historical information, all the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve number of risks and uncertainties. Although Suven Pharmaceuticals attempts to be accurate in making these statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven Pharmaceuticals may not undertake to update any forward-looking statements that may be made from time to time.

CIN: U24299TG2018PLC128171

6/F, Serene Chambers, Rd#7, Banjara Hills Hyderabad 500034, India
 Tel: 9140 2354 1142 Fax: 9140 2354 1152 Email: info@suvenpharm.com